Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol

References

• ManninoDMCOPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneityChest20021215 Suppl121S126S12010839
   PubMed Web of Science ®Google Scholar
• ManninoDMHomaDMAkinbamiLJFordESReddSCChronic obstructive pulmonary disease surveillance – United States, 1971–2000MMWR Surveill Summ2002516116
   Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD2017 Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed December 15, 2016
   Google Scholar
• KesslerRFallerMFourgautGMennecierBWeitzenblumEPredictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199915911581649872834
   PubMed Web of Science ®Google Scholar
• Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic SocietyAm J Respir Crit Care Med19951525 Pt 2S77S1217582322
   PubMed Web of Science ®Google Scholar
• HurstJRWedzichaJAChronic obstructive pulmonary disease: the clinical management of an acute exacerbationPostgrad Med J20048094749750515356350
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood InstituteMorbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases2009 Available from: https://ecopmc.files.wordpress.com/2012/04/2009_chartbook.pdfAccessed September 12, 2016
   Google Scholar
• PasqualeMKSunSXSongFHartnettHJStemkowskiSAImpact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare populationInt J Chron Obstruct Pulmon Dis2012775776423152680
   PubMed Web of Science ®Google Scholar
• LindenauerPKPekowPGaoSCrawfordASGutierrezBBenjaminEMQuality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary diseaseAnn Intern Med20061441289490316785478
   PubMed Web of Science ®Google Scholar
• AminABolluVKStenslandMDNetzerLGanapathyVTreatment patterns for patients hospitalized with acute exacerbations of chronic obstructive pulmonary diseaseAm J Health Syst Pharm2017
   Web of Science ®Google Scholar
• ChowLParulekarADHananiaNAHospital management of acute exacerbations of chronic obstructive pulmonary diseaseJ Hosp Med201510532833925820201
   PubMed Web of Science ®Google Scholar
• DhandRDolovichMChippsBMyersTRRestrepoRFarrarJRThe role of nebulized therapy in the management of COPD: evidence and recommendationsCOPD201291587222292598
   PubMedGoogle Scholar
• ButtiniFRossiIDi CuiaMCombinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patientsInt J Pharm20165021–224224826854429
   PubMed Web of Science ®Google Scholar
• TurnerMOPatelAGinsburgSFitzGeraldJMBronchodilator delivery in acute airflow obstruction. A meta-analysisArch Intern Med199715715173617449250235
   PubMedGoogle Scholar
• ChenYJMakinCBolluVKNavaieMCelliBRExacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonistsJ Med Econ2016191112026357881
   PubMed Web of Science ®Google Scholar
• Rodríguez-RoisinRThe airway pathophysiology of COPD: implications for treatmentCOPD20052225326217136952
   PubMedGoogle Scholar
• AalbersRAyresJBackerVFormoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trialEur Respir J200219593694312030736
   PubMed Web of Science ®Google Scholar
• BaumgartnerRAHananiaNACalhounWJSahnSASciarappaKHanrahanJPNebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trialClin Ther200729226127817472819
   PubMed Web of Science ®Google Scholar
• KingPRole of arformoterol in the management of COPDInt J Chron Obstruct Pulmon Dis20083338539118990965
   PubMedGoogle Scholar
• HandleyDASenanayakeCHDutczakWBiological actions of formoterol isomersPulm Pharmacol Ther200215213514512090787
   PubMed Web of Science ®Google Scholar
• HananiaNADonohueJFNelsonHThe safety and efficacy of arformoterol and formoterol in COPDCOPD201071173120214460
   PubMedGoogle Scholar
• ThomasJWGuireKEHorvatGGIs patient length of stay related to quality of care?Hosp Health Serv Adm199742448950710174462
   PubMedGoogle Scholar
• United States CongressHealth Insurance Portability and Accountability Act of 19961996 Available from: http://www.gpo.gov/fdsys/pkg/PLAW-104publ191/html/PLAW-104publ191.htmAccessed September 10, 2016
   Google Scholar
• PutchaNHanMKMartinezCHthe COPDGene® InvestigatorsComorbidities of COPD have a major impact on clinical outcomes, particularly in African AmericansChronic Obstruct Pulm Dis201411105114
   PubMedGoogle Scholar
• PutchaNPuhanMADrummondMBA simplified score to quantify comorbidity in COPDPLoS One2014912e11443825514500
   PubMed Web of Science ®Google Scholar
• QuanHSundararajanVHalfonPCoding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative dataMed Care200543111130113916224307
   PubMed Web of Science ®Google Scholar
• WierLMElixhauserAPfuntnerAAuDHOverview of hospitalizations among patients with COPD, 20082011 Available from: http://www.ncbi.nlm.nih.gov/books/NBK53969/?report=printableAccessed September 10, 2016
   Google Scholar
• BolluVErnstFRKarafilidisJRajagopalanKRobinsonSBBramanSSHospital readmissions following initiation of nebulized arfor-moterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPDInt J Chron Obstruct Pulmon Dis2013863163924353413
   PubMed Web of Science ®Google Scholar
• LindenauerPKShiehMSPekowPSStefanMSUse and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary diseaseAnn Am Thorac Soc20141181186119425167078
   PubMedGoogle Scholar
• SniderJTJenaABLinthicumMTEffect of hospital use of oral nutritional supplementation on length of stay, hospital cost, and 30-day readmissions among Medicare patients with COPDChest201514761477148425357165
   PubMed Web of Science ®Google Scholar
• Premier, IncPremier Research Services creates insights through data2017 Available from: https://www.premierinc.com/transforming-healthcare/healthcare-performance-improvement/premier-research-services/Accessed February 7, 2017
   Google Scholar
• MhannaMJKoesterJFCohnRCEffects of (r,r)- and (r,r/s,s)-formoterol on airway relaxation and contraction in an experimental rat modelCurr Ther Res Clin Exp200768424926124683215
   PubMed Web of Science ®Google Scholar
• DonohueJFHananiaNAMakeBOne-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPDChest201414661531154225451347
   PubMed Web of Science ®Google Scholar
• DonohueJFHananiaNASciarappaKAArformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and toleranceTher Adv Respir Dis200822374819124357
   PubMedGoogle Scholar
• SullivanSDRamseySDLeeTAThe economic burden of COPDChest20001172 Suppl5S9S10673466
   PubMed Web of Science ®Google Scholar